Cargando…
Harnessing Synthetic Lethal Interactions for Personalized Medicine
Two genes are said to have synthetic lethal (SL) interactions if the simultaneous mutations in a cell lead to lethality, but each individual mutation does not. Targeting SL partners of mutated cancer genes can kill cancer cells but leave normal cells intact. The applicability of translating this con...
Autor principal: | Shieh, Grace S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779047/ https://www.ncbi.nlm.nih.gov/pubmed/35055413 http://dx.doi.org/10.3390/jpm12010098 |
Ejemplares similares
-
Harnessing synthetic lethality to predict the response to cancer treatment
por: Lee, Joo Sang, et al.
Publicado: (2018) -
Moving ahead on harnessing synthetic lethality to fight cancer
por: Jerby-Arnon, Livnat, et al.
Publicado: (2015) -
Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine
por: Murata, Stephen, et al.
Publicado: (2016) -
Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response
por: Mandal, Jayaprakash, et al.
Publicado: (2022) -
Attenuating the emergence of anti-fungal drug resistance by harnessing synthetic lethal interactions in a model organism
por: Usher, Jane, et al.
Publicado: (2019)